SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof, or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof, and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.
-
Citations
65 Claims
- 1. A compound of formula (A) or (B):
- 18. A compound of formula (D):
- 19. A compound of formula (D-I):
- 20. A compound of formula (E):
-
21. A compound of formula (F) or (G):
- 28. A compound of formula (E-I):
- 40. A compound of formula (K):
- 45. A compound of formula (M):
- 48. A compound having the formula (N):
- 51. A compound of formula (P):
-
54. A compound having the structure:
Specification